DIACCURATE
8.7.2021 08:02:16 CEST | Business Wire | Press release
DIACCURATE, a French biotechnology company that develops sole-in-class therapeutics in immunotherapy, oncology and infectiology today announced the formation of its Scientific Advisory Board (SAB). Composed of 6 independent world-leading experts in the fields of basic and translational immunology, lipid metabolism, oncology and immunotherapy DIACCURATE’s SAB is chaired by Professor Tasuku HONJO, Kyoto University’s Institute for Advanced Study (KUIAS), awarded by the 2018 NOBEL PRIZE in Physiology or Medicine for his discovery of "immune checkpoint inhibitors", a key step in the history of cancerology.
Dr. Dominique BRIDON, CEO of DIACCURATE , commented: "We feel honored to have gathered this world-renowned group of experts in our newly formed Scientific Advisory Board around Prof. Jacques THÈZE, CSO and Scientific co-Founder of DIACCURATE”. He added: “We look forward to building on their exceptional knowledge and complementary experience in immunology, immunotherapy and oncology to progress our highly original and ambitious pipeline towards the clinic.”
“Cancer treatment has seen a revolution in immunotherapy. Extensive research to which my lab has contributed has brought to light the importance of cytotoxic CD8 T cells in the antitumor immune response, giving rise to current immune checkpoint inhibitors. But the role of CD4 T cells in this response had so far remained overlooked”, said Prof. Tasuku HONJO, Deputy Director-General of KUIAS and Chairman of DIACCURATE’s SAB . He explained: “Recent findings have demonstrated the key contribution of CD4 T cells to clinical efficacy of PD-L1/PD-1 blockade therapies.The developments undertaken at DIACCURATE to boost CD4 T cells functionality could represent a major step towards improving immunotherapy.”
Prof. Christoph HUBER, co-founder of the mRNA vaccine pioneer BioNTech, board member of the International Association of Cancer Immunotherapy and member of DIACCURATE’s SAB , added: “As we have seen once again with the COVID-19 pandemic, vaccines are an unvaluable immunotherapy tool to prevent and treat diseases that affect the immune system. It has been well known for over a century in the field of infectious diseases, it is also becoming an evidence in the field of oncology, and strategies like that of DIACCURATE that potentiate CD4 T cells response are expected to further improve the efficacy and the profile of vaccines”.
Dr. Bernard MALISSEN, Founder and Director of the Center for Immunophenomics, team leader and former Director of the Centre d'Immunologie de Marseille Luminy and member of DIACCURATE’s SAB , concluded: “Intricate biological networks control physiological and pathologic processes and revolve around biological switches. By integrating incoming signals and determining the downstream pathways that need to be activated, they constitute key “decision makers”. DIACCURATE has laid solid foundations to take on the challenge of targeting such biological switches, which are of tremendous importance in various pathological contexts, including cancer and infectious diseases”.
DIACCURATE
DIACCURATE is a late preclinical stage biotechnology company that invests the new frontiers of immunotherapy and oncology, firstly CD4 immunotherapy and targeted chemotherapy. At the forefront of translational medicine, these sole-in-class drug candidates target incurable diseases: refractory acute myeloid leukemia, pancreatic cancer and AIDS. DIACCURATE is conducting 3 proprietary development programs and expects to start its first clinical trial by 2022.
DIACCURATE is supported by a high-level management team led by Dr. Dominique BRIDON and world-class Board of Directors and Scientific Advisory Board chaired by Dr. Philippe POULETTY, CEO of TRUFFLE, and Prof. Tasuku HONJO, 2018 Nobel Prize in Medicine.
For more information, visit www.diaccurate.com and follow @DiaccurateTx
TRUFFLE CAPITAL
Created in 2001, TRUFFLE CAPITAL is an independent European Venture Capital company, specialising in life sciences (MedTech and Biotech) and in breakthrough IT technologies (FinTech and InsurTech). The mission of TRUFFLE CAPITAL is to help the creation and development of young innovating companies, capable of becoming tomorrow’s leaders.
Chaired by Patrick KRON and led by Dr. Philippe POULETTY et Bernard-Louis ROQUES, co-founders and CEOs, TRUFFLE CAPITAL has raised over €1.1 billion since its inception and helped over 70 companies in the digital technology and life sciences sectors. In 2019, TRUFFLE CAPITAL announced having raised almost €400 million in new institutional funds, including €250 million for new BioMedTech investments.
For more information, visit www.truffle.com and follow @trufflecapital
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005604/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global and China Gas Announce Increased Long-Term LNG Agreement18.11.2026 01:00:00 CET | Press release
Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of an increased Sales and Purchase Agreement (SPA) for the total purchase of 1.0 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement upsizes the previous SPA announced by the two parties in September 2026 for the purchase of 0.5 MTPA by another newly-agreed 0.5 MTPA. Venture Global’s total current long-term offtake with China Gas is now 3.0 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to continue growing our LNG partnership with China Gas, a leading natural gas operator in China, and help meet the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects,” said Venture Global CEO Mike Sabel. "We are pleased to further expa
UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 22:00:00 CET | Press release
Planned acquisition enhances how UPS serves time-critical complex healthcare needs across Asia Pacific region UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products rea
Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit
Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release
Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide
TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release
Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
